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Abstract: We compared the efﬁ  cacy and safety of preemptive vs postoperative dosing of 
lumiracoxib 400 mg in patients undergoing minor ambulatory arthroscopic knee surgery. Eligible 
patients were randomized to preemptive lumiracoxib, postoperative lumiracoxib, and placebo. 
The main efﬁ  cacy parameter was pain intensity (PI) (0–100 mm visual analog scale) in the target 
knee upon movement, 2 hours after surgery. Other efﬁ  cacy variables included PI in the target 
knee at rest and upon movement at 1, 3, 4, and 24 hours, time to ﬁ  rst rescue medication intake. 
In the lumiracoxib preemptive and postoperative groups, the estimated treatment difference 
compared to placebo for primary endpoint was –4.0 (95% CI: –9, –1; p = 0.007) and –3.5 (95% 
CI: –8.5, 0; p = 0.052), respectively. There was no statistical signiﬁ  cant difference between two 
active treatment groups (p = 0.602). Both preemptive and postoperative lumiracoxib resulted 
in signiﬁ  cantly lower PI scores at rest and after movement at all time-points and no statistically 
signiﬁ  cant difference was observed between the active treatments. Time to rescue medication 
intake was comparable for both active treatments. The proportion of adverse events was similar 
among all groups. We conclude that the efﬁ  cacy of lumiracoxib 400 mg is not affected by the 
timing of administration (preemptive or postoperative).
Keywords: arthroscopy, arthroscopic knee surgery, lumiracoxib, NSAIDs, postoperative pain, 
preemptive dosing
Introduction
Arthroscopy has reduced morbidity and duration of hospitalization related to 
orthopedic surgery and the knee is the most commonly arthroscoped joint (Villar 
1994). The sensory signals, following surgical trauma however trigger a prolonged 
state of increased excitability in the central nervous system (CNS) and later, result in 
the development of chronic pain after surgery (Woolf and Chong 1993). Hence many 
researchers have focused on methods to prevent these central neuroplastic changes 
through the utilization of preemptive or preventive analgesic techniques (Reuben and 
Buvanendran 2007).
Nonsteroidal antiinflammatory drugs (NSAIDs) attenuate the inflammatory 
response; reduce the peripheral sensitization and the induction, and maintenance of 
central sensitization. The central analgesic actions of NSAIDs may contribute to a 
preemptive analgesic effect by averting spinal prostaglandin synthesis and reducing 
pre- and postsynaptic release of neurotransmitters from the primary afferent terminals 
and spinal interneurons (Katz 2001).
One of the major disadvantages of administering traditional NSAIDs before 
orthopedic surgery is the risk of perioperative bleeding. This risk is attributed to 
antiplatelet effects of traditional NSAIDs via. cyclo-oxygenase (COX)-1 isoenzyme 
(Robinson et al 1993; Legeby et al 2005). Selective COX-2 inhibitors have emerged Journal of Pain Research 2008:1 28
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as a class of analgesic agents that offer pain relief similar 
to nonselective NSAIDs without compromising platelet 
aggregation and with reduced gastrointestinal (GI) toxicity 
(Romsing and Moiniche 2004). Reuben and Connelly 
(2000) have shown that preoperative administration of 
selective COX-2 inhibitors are effective in the treatment of 
postoperative pain, and are not associated with an increase 
in perioperative blood loss.
Perioperative use of a COX-2 inhibitor reduces 
opioid consumption, pain, vomiting, sleep disturbance, 
and improves the range of motion after total knee 
arthroplasty (Buvanendran et al 2003). Lumiracoxib is the 
ﬁ  rst carboxyl, nonsulphur-containing, selective COX-2 
inhibitor with anti-inﬂ  ammatory, analgesic, and antipyretic 
effects comparable with traditional NSAIDs, but with much 
improved GI safety proﬁ  le (Schnitzer et al 2004; Esser 
et al 2005). Lumiracoxib has unique pharmacokinetics as 
its metabolites are retained in the inﬂ  amed tissues, and 
its synovial ﬂ  uid half-life is higher than plasma half-life 
(Scott et al 2004).
Lumiracoxib is effective in treating acute pain conditions 
such as postoperative dental pain (Kellstein et al 2004; 
Zelenakas et al 2004; Fricke et al 2008), acute gout 
(Willburger et al 2006), arthroplasty (Chan et al 2005), 
primary dysmenorrhoea (Daniels et al 2008), and sprains 
and strains (Kyle et al 2006). Lumiracoxib is indicated at a 
dose of 100 mg once daily for chronic use in osteoarthritis, 
and at doses of 200 mg or 400 mg once daily for short-term 
use in acute pain indications. While liver toxicity is a known 
rare but serious side effect of all COX-2 inhibitors and 
traditional NSAIDs (Traversa et al 2003), there have been 
some speciﬁ  c concerns from health authorities regarding 
the hepatic proﬁ  le of lumiracoxib. Australia withdrew 
lumiracoxib in August 2007 following reports of severe 
liver events occurring predominantly at doses higher than 
lumiracoxib 100 mg once daily taken chronically. The US 
Food and Drug Administration (FDA) issued a nonap-
provable letter in September 2007, citing concerns over 
the hepatic proﬁ  le of lumiracoxib. This was followed by 
withdrawals in Canada, Europe, and a few other coun-
tries. Assessment of the beneﬁ  t–risk proﬁ  le of the drug is 
ongoing by a number of health authorities (Fleischmann 
et al 2008).
The present study was designed to compare the 
efﬁ  cacy and safety of preemptive vs postoperative dosing 
of lumiracoxib 400 mg (Novartis Pharma AG, Basel, 
Switzerland) in patients who underwent minor ambulatory 
arthroscopic knee surgery.
Methods
This was a multi-center, randomized, double-blind, 
placebo-controlled, parallel-group study. The study was 
performed in compliance with the guidelines for good clinical 
practice and in accordance with the Declaration of Helsinki. 
Ethics committee approval from all participating institutions 
was obtained. Patients, investigator staff, persons performing 
the assessments, data analysts, and clinical team members 
were blinded to the identity of the treatment.
Study populations
Male or female outpatients (aged at least 18 years) who had 
signed a written informed consent and were scheduled for 
minor ambulatory arthroscopic knee surgery (eg, removal, 
trimming, shaving or repair of meniscal or articular cartilage 
including lavage) were included in the study, with the 
exclusion of only diagnostic arthroscopy. The determination 
of sample size was based on the results of a similarly designed 
single centre study (Reuben et al 2002).
Patients with a history of hypersensitivity or allergy 
to narcotics, NSAIDs or any COX-2 inhibitors, drug or 
alcohol abuse, peptic ulcer, gastroesophageal reﬂ  ux disease, 
inflammatory bowel disease and any cardiovascular, 
hepatobiliary and pancreatic and renal disorder were 
excluded from the study. Patients taking anticoagulants and 
anti-platelet aggregation agents (except low-dose aspirin 
for cardioprotection) and pregnant or lactating females 
were also excluded.
All surgical procedures were performed under local 
anesthesia, using 30 ml intra-articular bupivacaine 0.25%. 
During surgery, patients received i.v. sedation with 
midazolam (1–3 mg) and propofol (10–100 μg/kg/min), and, 
an additional 30 ml of intra-articular bupivacaine 0.25% was 
injected through the arthroscope at the end of the surgery.
Study design
Eligible patients were randomized (2:2:1) to receive 
lumiracoxib 400 mg given preemptively (1 hour before the 
start of surgery), lumiracoxib 400 mg given postoperatively 
(15 min after the completion of surgery), or placebo. Patients 
in the ﬁ  rst group received a single dose of lumiracoxib 
400 mg 1 hour before surgery and a placebo tablet 15 min 
after surgery (Preemptive group), patients in the second 
group received a placebo tablet 1 hour before surgery and 
a single dose of lumiracoxib 400 mg 15 min after surgery 
(Postoperative group), and patients in the third group received 
a placebo tablet both 1 hour before and again 15 min after 
surgery (Placebo group). Patients were monitored during the Journal of Pain Research 2008:1 29
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24-hour period after the surgery and they were asked to come 
back for a ﬁ  nal visit approximately 24 hours after surgery.
Assessment of postoperative pain intensity was performed 
using a 0–100 mm visual analog scale (VAS). Pain intensity 
scores were recorded both at rest and after movement at 1, 2, 
3, 4, and 24 hours after completion of surgery. The primary 
efﬁ  cacy endpoint was the reduction in pain intensity in the 
target knee after movement at the 2 hour time-point. Pain 
score after movement was recorded immediately after the 
patient actively ﬂ  exed the operated knee to the 90° position. 
Missing pain intensity scores were imputed by last observa-
tion carried forward method (LOCF).
The secondary efﬁ  cacy endpoints included the reduction 
in pain intensity at 1, 2, 3, 4 and 24 hour time-points while 
at rest and reduction in pain intensity at 1, 3, 4 and 24 hour 
time-points after movement, the time to ﬁ  rst rescue medica-
tion intake, and the patient’s global evaluation of response to 
the study medication (using a ‘four-point’ Likert scale at the 
end of the study when patients rated the study medication as 
either poor, fair, good, or excellent).
The use of oral paracetamol 500 mg was permitted 
during the screening period until 12 hours before surgery. 
After surgery oral paracetamol 1000 mg was provided 
as the rescue medication and if needed, addition of oral 
oxycodone 10 mg was allowed. Systemic corticosteroids, 
opiates, anticoagulants, other NSAIDs and antiplatelet 
agents (except low-dose aspirin for cardioprotection) were 
not allowed as concomitant therapies. Safety assessments 
consisted of collecting all adverse events (AEs), serious 
adverse events (AEs meeting one of the following criteria: 
fatal or life-threatening; resulting in disability/incapacity; 
birth defects; requires or prolongs hospitalization; or is 
medically signiﬁ  cant, ie, deﬁ  ned as an event that jeopardizes 
the patient or may require intervention to prevent one of the 
outcomes listed above), with their severity, duration and 
relationship to study drug, and pregnancies. The occurrence 
of AEs was sought by nondirective questioning or they were 
detected when volunteered by the patient. Adverse events 
were summarized by presenting the number and percentage of 
patients having any AE, having an AE in each system organ 
class and having each individual AE. Adverse events were to 
be described by the investigator by severity (mild, moderate 
or severe AE). Assessments of physical condition and vital 
signs were also a part of the safety assessment.
Statistical analyses
The intent-to-treat (ITT) population was the primary 
population for efficacy analyses and consisted of all 
randomized patients who received at least one dose of study 
medication. The per-protocol (PP) population consisted of 
all ITT patients who were not major protocol violators. The 
safety population included all patients who received at least 
one dose of study medication. Assuming a dropout rate of 
8%, a total of 110 patients and at least 39 patients in the 
active treatment groups were required for the evaluation the 
primary efﬁ  cacy variable. In order to minimize the number of 
patients treated with placebo, a 2:2:1 randomization scheme 
was used. Comparisons of median values of time speciﬁ  c 
pain intensity (both at rest and after movement) were made 
relative to placebo and between active treatments using 
the Wilcoxon’s rank sum test stratiﬁ  ed by the center and 
the Hodges–Lehmann estimate of the median difference. 
The time to ﬁ  rst rescue medication was measured from 
the end of surgery using a logrank test, and Kaplan–Meier 
estimates for the fraction of patients who did not take rescue 
medication were plotted. Patient’s global evaluations were 
summarized using the Cochran–Mantel–Haenszel test after 
adjusting for center.
Results
One hundred and ten patients were enrolled in the study 
and all of them were randomized (2:2:1) to lumiracoxib 
preemptive (n = 45), lumiracoxib postoperative (n = 44), 
and placebo (n = 21) (Figure 1). All patients completed the 
study without discontinuations. Patient demographics are 
shown in Table 1. Treatment groups were comparable for the 
mean weight, body mass index (BMI) and race. All patients 
were Caucasian. Majority of patients were in the age range 
of 41 to 64 years, with the placebo group having a smaller 
percentage of patients in the lower age group (less than 40) 
than the two active treatment arms.
The surgery performed was similar across the three 
groups. Removal of meniscal cartilage and shaving of 
articular cartilage were the most common types of surgery 
performed for all treatment groups. The duration of surgery 
was similar across the three treatment groups (mean values: 
30.6–31.8 min). The lumiracoxib postoperative group had 
the lowest maximum duration (Table 2).
Preemptive dosing with 400 mg lumiracoxib resulted 
in lower median pain intensity scores than postoperative 
dosing or placebo. The estimated difference in median pain 
intensity compared to placebo was statistically signiﬁ  cant in 
both active treatment groups. Although the mean and median 
scores of pain intensity were lower for the lumiracoxib 
preemptive group than for the postoperative lumiracoxib 
group, the Hodges–Lehmann estimate of the difference was Journal of Pain Research 2008:1 30
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Randomization of eligible
population  (n = 110)
Lumiracoxib 400 mg
postoperative
Lumiracoxib 400 mg
postoperative Placebo
Randomized population,
n = 21
Randomized population,
n = 44
Randomized population,
n = 45
Safety population,
n = 45
Safety population,
n = 44
Safety population,
n = 21
 ITT
 population, n = 21
 ITT population, 
n = 44
 ITT population, 
n = 45
 Completing the study, 
n = 45 (100%)
 Completing the study, 
n = 44 (100%)
 Completing the study, 
n = 21 (100%)
 Articular/Meniscal
 Surgery not performed,
n = 1 (2.2%)
 Duration of surgery
 more than 1.5 hours,
 n = 1 (2.2%)
 Pre-dose taken >1.5
 hours before surgery,
 n = 1 (2.2%)
Prohibited medicine
taken after surgery,
n = 2 (4.4%)
Discontinuations (n = 0)
Major protocol
violations,  n = 5  (11.1%)
Discontinuations (n = 0)
Major protocol
violations, n = 1  (2.3%)
 Articular/Meniscal
 Surgery not performed,
n = 0
 Duration of surgery
 more than 1.5 hours,
 n = 0
 Pre-dose taken >1.5
 hours before surgery,
 n = 0
Prohibited medicine
taken after surgery,
n = 1 (2.3%)
Discontinuations (n = 0)
Major protocol
violations, n = 0  (0%)
 Articular/Meniscal
 Surgery not performed,
n = 0
 Duration of surgery
 more than 1.5 hours,
 n = 0
 Pre-dose taken >1.5
 hours before surgery,
 n = 0
Prohibited medicine
taken after surgery,
n = 0
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Table 1 Demographic summary of the treatment groups (safety population)
Lumiracoxib 400 mg 
preemptive N = 45 n (%)
Lumiracoxib 400 mg 
postoperative N = 44 n (%)
Placebo N = 21 
n (%)
All groups N = 110 
n (%)
Age (years) Mean ± SD 50 ± 18.2 51.8 ± 13.8 55.8 ± 9.5 51.8 ± 15.1
Age group n (%)
  18–40 years 16 (35.6) 9 (20.5) 1 (4.8) 26 (23.6)
  41–64 years 17 (37.8) 27 (61.4) 14 (66.7) 58 (52.7)
  >64 years 12 (26.7) 8 (18.2) 6 (28.6) 26 (23.6)
Gender n (%)
  male 20 (44.4) 25 (56.8) 10 (47.6) 55 (50.0)
  female 25 (55.6) 19 (43.2) 11 (52.4) 55 (50.0)
Race (Caucasian) n (%) 45 (100) 44 (100) 21 (100) 110 (100)
Weight (kg) Mean ± SD 79.9 ± 14.0 82.1 ± 16.0 87.9 ± 16.4 82.3 ± 15.4
BMI (kg/m2) Mean ± SD 27.6 ± 4.7 28.01 ± 5.7 29.4 ± 4.4 28.1 ± 5.1
Abbreviations: BMI, body mass index; SD, standard deviation.
Table 2 Surgical summary of the treatment groups (safety population)
Lumiracoxib 400 mg 
preemptive N = 45
Lumiracoxib 400 mg 
postoperative N = 44
Placebo N = 21 Total N = 110
Duration of surgery (minutes) 
Mean ± SD
31.8 ± 14.8 30.6 ± 11.9 31.7 ± 17.8 31.3 ± 14.3
Cartilage surgery, number (%) of patients
 Articular 27 (60.0%) 27 (61.4%) 15 (71.4%) 69 (62.7%)
  Type of surgery performed
    Remove 2 (4.4%) 4 (9.1%) 0 6 (5.5%)
    Trimming 5 (11.1%) 10 (22.7%) 7 (33.3%) 22 (20.0%)
    Shave 21 (46.7%) 15 (34.1%) 9 (42.9%) 45 (40.9%)
    Repair 1 (2.2%) 1 (2.3%) 1 (4.8%) 3 (2.7%)
 Meniscal 38 (84.4%) 37 (84.1%) 18 (85.7%) 93 (84.5%)
  Type of surgery performed
    Remove 27 (60.0%) 33 (75.0%) 15 (71.4%) 75 (68.2%)
    Trimming 7 (15.6%) 7 (15.9%) 0 14 (12.7%)
    Shave 5 (11.1%) 3 (6.8%) 5 (23.8%) 13 (11.8%)
  Repair 2  (4.4%) 0 0 2  (1.8%)
Both articular and meniscal 21 (46.7%) 20 (45.5%) 12 (57.1%) 53 (48.2%)
Neither articular or meniscal 1 (2.2%) 0 0 1 (0.9%)
Abbreviation: SD, standard deviation.
however not statistically signiﬁ  cant (Table 3). The results of 
per protocol (PP) analysis conﬁ  rmed that both preemptive and 
postoperative lumiracoxib 400 mg were signiﬁ  cantly better 
at relieving pain following arthroscopic knee surgery than 
placebo, but preemptive dosing did not have a signiﬁ  cant 
beneﬁ  t over postoperative.
Both preemptive and postoperative lumiracoxib dosing 
resulted in signiﬁ  cantly lower pain intensity scores than 
placebo at rest and after movement at all time-points, with the 
exception of postoperative dosing at rest at 1 hour and after 
movement at 2 hours. There was no statistically signiﬁ  cant 
difference in pain intensity (at any time-point at rest and after 
movement) and time to ﬁ  rst rescue medication intake between 
the active treatment groups (Figure 2A and B). The time to 
rescue medication intake was signiﬁ  cantly longer for both 
preemptive (p = 0.003) and postoperative lumiracoxib groups 
(p = 0.001) compared with placebo (Figure 3). The use of the 
rescue medication use is summarized in Table 4.Journal of Pain Research 2008:1 32
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Table 3 Analysis of pain intensity (after movement) at 2 hours postsurgery (ITT population, LOCF)
Contrast p-value† Estimated difference 95% CI*
Primary contrast
Preemptive lumiracoxib 400 mg vs postoperative 
lumiracoxib 400 mg
0.602 0.0 −2.0, 1.0
Secondary contrast
Preemptive lumiracoxib 400 mg vs placebo 0.007 −4.0 −9.0, –1.0
Postoperative lumiracoxib 400 mg vs placebo 0.052 −3.5 −8.5, 0.0
Notes: †Wilcoxon’s rank sum test stratiﬁ  ed by center; *95% CI for the Hodges–Lehmann estimate of the difference.
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Placebo (n = 21)
(a) After movement
30
25
20
15
10
5
0
(b) At rest
30
25
20
15
10
5
0
1           2           3          4                                                  24 
Time point (hours post-surgery)
Time point (hours post-surgery)
1           2          3           4                                               24
M
e
d
i
a
n
 
s
c
o
r
e
 
(
1
0
0
 
m
m
 
V
A
S
)
M
e
d
i
a
n
 
s
c
o
r
e
 
(
1
0
0
 
m
m
 
V
A
S
)
*
*
*
*
*
*
* * *
**
**
*
**
*
**
†
†
†† †
†
†††
††
†
†
†
Figure 2 Pain intensity over time (ITT population, LOCF).
Notes: *p  0.05;  **p  0.01;  ***p  0.001 lumiracoxib 400 mg preemptive vs placebo;  
†p  0.05; ††p  0.01;   †††p  0.001 lumiracoxib 400 mg postoperative vs placebo; No 
signiﬁ  cant differences were observed between given preemptive and postoperative 
lumiracoxib 400 mg; Wilcoxon rank sum test stratiﬁ  ed by center.
Majority of patients in the lumiracoxib preemptive and 
postoperative treatment groups assessed their medication 
as “excellent” (71.1% and 70.5%, respectively) in contrast 
to 38.1% in placebo. This difference was signiﬁ  cant in 
both preemptive ( p = 0.012) and postoperative ( p = 0.014) 
lumiracoxib groups compared to the placebo group. 
There was no signiﬁ  cant difference between the active 
lumiracoxib groups ( p = 0.945).
Adverse events were mild or moderate and transient in 
nature. The proportion of patients with AEs was slightly 
greater for the placebo (4.8%) group than the lumiracoxib 
preemptive (4.4%) and postoperative (4.5%) groups. No 
signiﬁ  cant difference was observed in the AEs between the 
treatment groups. No SAEs were reported during this study 
(Table 5).
Discussion
Postoperative pain is mostly caused by several components 
and reasons involving ongoing sensory signals generated 
from the damaged tissue that may lead to modiﬁ  cation in 
CNS function. The underlying principle behind preemptive 
analgesia is that the therapeutic intervention is made in 
advance to the pain rather than in reaction to it (Woolf and 
Chong 1993). This study found that administration of both 
preemptive and postoperative lumiracoxib 400 mg was 
Lumiracoxib- 400 mg preemptive (n = 45)†
Lumiracoxib- 400 mg post-operative(n = 44)‡
Placebo (n = 21)
Time-to-first rescue medication (Hours)
0        2       4        6       8       10     12      14     16      18     20      22      24
0
10
20
30
40
50
60
P
e
r
c
e
n
t
a
g
e
 
o
f
 
p
a
t
i
e
n
t
s
 
u
s
i
n
g
 
r
e
s
c
u
e
 
m
e
d
i
c
a
t
i
o
n
Figure 3 Time to ﬁ  rst rescue medication (ITT population).
Notes: †p = 0.003 vs placebo, ‡p = 0.001 vs placebo; n = intent-to-treat patients per 
treatment group; p-values calculated using logrank test.Journal of Pain Research 2008:1 33
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Table 4 Summary of rescue medication use (safety population)
Lumiracoxib 400 mg 
preemptive N = 45
Lumiracoxib 400 mg 
postoperative N = 44
Placebo N = 21 Total N = 110
No (%) of patients who took 
rescue medication
9 (20.0%) 7 (15.9%) 11 (52.4%) 27 (24.5%)
No (%) of patients who took ﬁ  rst dose of rescue medication
Prior to the 1 hour assessment 1 (2.2%) 1 (2.3%) 0 (0.0%) 2 (1.8%)
Prior to the 2 hour assessment 1 (2.2%) 1 (2.3%) 1 (4.8%) 3 (2.7%)
Prior to the 3 hour assessment 2 (4.4%) 1 (2.3%) 1 (4.8%) 4 (3.6%)
Prior to the 4 hour assessment 2 (4.4%) 2 (4.5%) 2 (9.5%) 6 (5.5%)
After the 4 hour assessment 7 (15.6%) 5 (11.4%) 9 (42.9%) 21 (19.1%)
signiﬁ  cantly better than placebo in relieving pain following 
minor arthroscopic knee surgery and signiﬁ  cantly delayed 
the ﬁ  rst rescue medication intake compared to placebo. 
Moreover, the majority of patients in the lumiracoxib 
treatment groups assessed their medication as “excellent”.
Preoperative administration of the COX-2 inhibitor reduces 
prostaglandin E2 and interleukin 6 levels in the cerebrospinal 
ﬂ  uid and at the surgical site. These molecules are related to 
the development of postoperative pain, sleep disturbance, 
and poor functional recovery (Buvanendran et al 2006). 
Preoperative NSAID administration is generally associated 
with clear beneﬁ  ts in terms of reduced postoperative pain, 
analgesic and antiemetic consumption and patient satisfaction 
compared with placebo (Straube et al 2005). However in this 
study when preemptive dosing was compared to postoperative 
dosing, no statistically signiﬁ  cant difference was observed. 
Also the time to first rescue medication intake was not 
statistically different between the active treatment groups.
There is a widespread belief in the efﬁ  cacy of preemptive 
analgesia (Moiniche et al 2002). However the benefit 
of preemptive versus postoperative analgesia remains 
controversial in the literature. The superior efficacy of 
preemptive versus postoperative NSAID administration has 
been shown in certain clinical trials (Pedersen et al 1993; 
Reuben et al 2002; Ong et al 2005) while not in others 
(Murphy and Medley 1993; Norris et al 2001; Moiniche et al 
2002). A metaanalysis of 20 trials comparing preincisional 
with postincisional NSAID or paracetamol found that some 
aspects of postoperative pain control were improved by 
preemptive treatment in four of the 20 trials. However, the 
overall data demonstrated that preemptive NSAIDs did not 
provide any superior analgesic beneﬁ  t when compared with 
postincisional administration of these drugs (Moiniche et al 
2002). This is in agreement with the ﬁ  ndings in our study.
Reuben and colleagues (2002) however observed signiﬁ  -
cant beneﬁ  t of preemptive dosing compared to postoperative 
dosing in patients undergoing ambulatory arthroscopic knee 
surgery. The inclusion criteria, exact timing of preemptive 
and postoperative dosing relative to surgery and the anesthetic 
management in our study were comparable with this reference 
study. Nevertheless other factors, eg, the extent and nature of 
tissue damage, extent and duration of surgery (mean dura-
tion of surgery was almost half compared to our study), and 
pharmacokinetics of the agent (longer half life of refecoxib), 
Table 5 Overall adverse events and affected system organ classes: n (%) of patients (safety population)
Lumiracoxib 400 mg 
preemptive N = 45 n (%)
Lumiracoxib 400 mg 
postoperative N = 44 n (%)
Placebo N = 21 n (%) Total N = 110 n (%)
Patients with AE(s) 2 (4.4) 2 (4.5) 1 (4.8) 5 (4.5)
System organ class
Cardiac disorders 0 0 1 (4.8) 1 (0.9)
  Angina pectoris 0 0 1 (4.8) 1 (0.9)
Gastrointestinal disorders 1 (2.2) 1 (2.3) 0 2 (1.8)
  Abdominal pain 0 1 (2.3) 0 1 (0.9)
  Vomiting 1 (2.2) 0 0 1 (0.9)
Nervous system disorders 1 (2.2) 1 (2.3) 0 2 (1.8)
  Headache 1 (2.2) 1 (2.3) 0 2 (1.8)Journal of Pain Research 2008:1 34
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could have led to different study populations and different 
outcomes. The pain intensities reported in our study are lower 
than expected and might have limited the sensitivity to detect 
a further improved outcome in patients receiving preemptive 
dosing of lumiracoxib. Finally, the anesthetic management 
(especially intra-articular bupivacaine at the end of the 
surgery), as applied in the centers participating in our study, 
may have been more effective in controlling the development 
of postsurgical pain and may have played a confounding 
effect by masking the treatment differences on pain intensity, 
especially at the early time-points. Similar preemptive and 
postoperative efﬁ  cacy comparison with other routinely used 
analgesics eg; paracetamol, ibuprofen, diclofenac, etc. warrant 
further studying.
In conclusion preemptive and postoperative administration 
of lumiracoxib 400 mg was equally effective in relieving pain 
following minor arthroscopic knee surgery.
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